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Abstract
Background: Treadmill exercise and airway clearance with the Flutter® device have previously been shown to improve
mucus clearance mechanisms in people with cystic fibrosis (CF) but have not been compared. It is therefore
not known if treadmill exercise is an adequate form of airway clearance that could replace established airway
clearance techniques, such as the Flutter®. The aim of this study was to evaluate respiratory flow, sputum properties
and subjective responses of treadmill exercise and Flutter® therapy, compared to resting breathing (control).
Methods: Twenty-four adults with mild to severe CF lung disease (FEV1 28–86% predicted) completed a three-day
randomised, controlled, cross-over study. Interventions consisted of 20 min of resting breathing (control), treadmill
exercise at 60% of the participant’s peak oxygen consumption and Flutter® therapy. Respiratory flow was measured
during the interventions. Sputum properties (solids content and mechanical impedance) and subjective responses
(ease of expectoration and sense of chest congestion) were measured before, immediately after the interventions
and after 20 min of recovery.
Results: Treadmill exercise and Flutter® resulted in similar significant increases in peak expiratory flow, but only
Flutter® created an expiratory airflow bias (i.e. peak expiratory flow was at least 10% higher than peak inspiratory flow).
Treadmill exercise and Flutter® therapy resulted in similar significant reductions in sputum mechanical impedance, but
only treadmill exercise caused a transient increase in sputum hydration. Treadmill exercise improved ease of
expectoration and Flutter® therapy improved subjective sense of chest congestion.
Conclusions: A single bout of treadmill exercise and Flutter® therapy were equally effective in augmenting mucus
clearance mechanisms in adults with CF. Only longer term studies, however, will determine if exercise alone is an
adequate form of airway clearance therapy that could replace other airway clearance techniques.
Trial registration: Australian and New Zealand Clinical Trials Registry, Registration number #ACTRN12609000168257,
Retrospectively registered (Date submitted to registry 26/2/2009, First participant enrolled 27/2/2009, Date registered 6/4/2009).
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Background
Cystic fibrosis (CF) lung disease is characterised by re-
duced hydration at the airway surface and dehydrated
mucus, [1] resulting in impaired mucus clearance that
leads to a cascade of inflammation and progressive lung
damage [2]. Interventions to improve mucus clearance
are integral to the respiratory management of CF [3].
Most therapies are required daily and adults with CF
report spending an average of 108 min on treatment activ-
ities each day, the majority of that time performing airway
clearance and exercise [4]. Strategies to combine effective
interventions to minimise treatment time are needed. Exer-
cise improves physical fitness and may also improve lung
function and quality of life in people with CF [5]. If exercise
also aids mucus clearance, it would reduce treatment time,
as exercise could substitute airway clearance interventions,
while gaining the other known benefits of exercise.
Airway clearance or physiotherapy techniques aim to
improve mucus clearance by the following mechanisms:
altering airflow (increasing the peak expiratory flow and
creating an expiratory airflow bias, with the ratio of peak
expiratory to peak inspiratory flow, PEF:PIF > 1.10); [6, 7]
improving the physical properties of the mucus; [8] poten-
tially increasing airway surface hydration; [9–13] and
coughing [14].
Treadmill exercise improves mucus clearance mecha-
nisms in CF by increasing PEF and reducing sputum
mechanical impedance [15]. Physiotherapy with a device
creating oscillating positive expiratory pressure, the
Flutter®, is an established form of airway clearance in CF
and is equally effective to other airway clearance tech-
niques [16]. The Flutter® improves mucus clearance
mechanisms in CF by increasing PEF and creating an
expiratory airflow bias, [17] as well as reducing sputum
mechanical impedance [18]. Exercise and Flutter®, how-
ever, have not been compared. Therefore, the aim of this
study was to determine the effects of treadmill exercise
and Flutter® therapy, compared to resting breathing (con-
trol), on respiratory flow (including airflow bias), sputum
properties and subjective responses in adults with CF.
Methods
Participants
Participants were recruited from the Adult CF Clinic at
Royal Prince Alfred Hospital, Sydney, Australia. Patients
were eligible for inclusion if they were at least 17 years
old, had a confirmed diagnosis of CF (genetic testing and/
or previous positive sweat test results) and their treating
physician deemed them to be clinically stable [19].
Patients were excluded if they had received a lung trans-
plant, were infected with Burkholderia cepacia complex
or were pregnant. Potential participants were volunteers
or personally approached by one of the researchers (TJD)
at either a routine clinic visit or at the end of a hospital
admission. Research procedures were approved by the
Sydney South West Area Health Service Ethics Committee
(Protocol X08-0175) and participants provided written
informed consent prior to trial enrolment.
Study design
The trial was a randomised, cross-over design, registered
with the Australian and New Zealand Clinical Trials
Registry (#ACTRN12609000168257). The study involved
four visits (Fig. 1). On Visit 1, participants’ spirometry
Fig. 1 Participant flow during the trial
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and lung volumes (via body plethysmograpy) (VMax229,
SensorMedics, Yorba Linda, USA) were measured ac-
cording to the American Thoracic Society/European
Respiratory Society guidelines [20, 21]. Participants then
completed an incremental peak treadmill exercise test,
according to a modified Balke protocol, [22] with
breath-by-breath measurement of ventilatory and meta-
bolic variables (VMax229 system) and pulse oximetry
(RadicalTM, Masimo, Irvine, USA). All exercise tests
were classified as maximal effort according to the cri-
teria outlined in the CF exercise testing guidelines [23].
Participants were taught to use the Flutter® device (Flut-
ter VRP1 valve®; Axcan Scandipharm Inc., Birmingham,
USA) by a senior physiotherapist. If participants were
using the Flutter® on a regular basis, any corrections
to their technique were made if necessary. After com-
pletion of all study procedures on Visit 1, participants
were randomised to the order of interventions for the
following three sessions (Visits 2, 3 and 4). Interven-
tion order was determined by computer-generated
randomisation (with a random integer generator on
www.random.org). Randomisation was performed by a
person not involved in the interventions on Visits 2,
3 and 4 and stored in sealed, sequentially numbered,
opaque envelopes.
On Visits 2, 3 and 4, participants completed the three-
day, randomised, cross-over study, according to the data
collection procedures in Fig. 2. Visits 2, 3 and 4 were
scheduled at the same time in the morning within a
one-week period (during which medication, airway clear-
ance and exercise regimens were unchanged). Partici-
pants were also asked to withhold routine mucolytic
therapy, airway clearance and exercise on the morning
of a trial visit. On each Visit 2, 3 and 4, sputum samples
were collected immediately before (pre) and after (post
+ 0) a 20-min intervention, and after a further 20 min of
resting breathing/recovery (post + 20). If participants
spontaneously expectorated a sputum sample in the five
minutes following the intervention (i.e. they were not
requested to do so), this was also collected (post + 5).
The three interventions were resting breathing (control),
constant-load treadmill exercise and Flutter® plus the
forced expiratory technique (FET), [24] from now on
referred to as “Flutter® therapy”.
Treatment interventions
For the control intervention, participants sat quietly for
20 min. For the exercise intervention, participants exer-
cised on the treadmill for 20 min at a constant work rate
equivalent to 60% of the peak oxygen consumption
(VO2) achieved in the incremental peak treadmill test on
Visit 1. This intensity and duration were chosen to repli-
cate a typical prescription used for exercise training [25].
The Flutter® therapy intervention consisted of breathing
through the Flutter® for 15 breaths, followed by relaxed
and deep breathing, huffing and coughing, according to
the FET [24]. This cycle was repeated six times. The
Flutter® angle/inclination was chosen for each participant
that maximised the sensation of vibrations within the
lungs [26] and held in a constant position with a clamp
during the intervention. The Flutter® angle was mea-
sured with an inclinometer.
Measurements
Respiratory flow
During each 20-min intervention, respiratory flow was
measured with a heated pneumotachograph (Hans
Rudolf model 3813, Hans Rudolf Inc., Kansas City,
USA), calibrated on each occasion, where scaling factors
were pre-determined by a rotameter (Model 2000 Fisher
Controls, Croydon, England). The Flutter® was attached
to the expiratory port of a two-way non-rebreathing
valve (2700 series, Hans Rudolf Inc.) in order to collect
inspiratory and expiratory flow (i.e. the participant in-
spired through the pneumotachograph and expired
through the pneumotachograph and Flutter®). Data were
collected at 125 Hz and flow signals were later analysed
by a blinded assessor using custom-made software
(PhysioDAQxs v3.0 and Breathalyser v1.0, University of
Sydney, Australia) to determine PEF and airflow bias
(PEF:PIF) for all interventions, and oscillation frequency
during the Flutter® intervention. For the Flutter® inter-
vention, respiratory flow was measured only whilst
participants breathed in and out through the Flutter®
(i.e. not during the FET component of the intervention).
Sputum properties
Sputum samples were manually separated from saliva
and stored in 1.2 mL tubes in a −80 °C freezer. The
Fig. 2 Data collection procedures on Visits 2, 3 and 4. Participants completed visual analogue scores for subjective sense of chest congestion and ease
of sputum expectoration with each sputum sample. A sputum sample was also collected five minutes after the intervention (post + 5) if spontaneously
expectorated (i.e. it was not requested from participants). Respiratory flow data were collected during the 20 min treatment and coughs were counted
during the 20 min treatment and rest/recovery periods
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storage tubes were coded, to ensure de-identification at
later analysis when measured by a blinded assessor.
Sputum analysis procedures were followed as reported
previously [15, 27, 28]. The sputum solids content per-
centage, from which inferences of airway hydration are
made, was estimated by measuring the weight of a 50 μL
aliquot of sputum before and after lyophilisation to
dryness for 24 h using a freeze dryer (Kinetics, Stone
Ridge, USA). Sputum elasticity (dynamic G´) and viscos-
ity (dynamic G´´) were measured using a 20 μL aliquot
of sputum and a controlled stress rheometer with geom-
etry 20 mm, 0.5° aluminium cone and plate over the
frequency of 1–100 rad/s (AR2000, TA Instruments,
New Castle, USA). The results were reported as sputum
mechanical impedance (G*), also known as rigidity
factor, which is the vector sum of viscosity and elasticity.
Sputum mechanical impedance values at 1 rad/s repre-
sent sputum properties during resting breathing and
mucociliary clearance, values at 100 rad/s represent
those during cough and cough clearance.
Cough
All coughs (spontaneous and those directed, according
to the FET) were manually counted during each 20-min
intervention and recovery period.
Subjective responses
For each requested sputum sample, participants recorded
on a 10 cm visual analogue scale the subjective sense of
chest congestion (0 = very congested, 10 = very clear) and
ease of expectoration (0 = very difficult to expectorate,
10 = very easy to expectorate). The visual analogue
scales were later measured by an assessor blinded to
the intervention.
Statistical analyses
Repeated measures ANOVA were performed to
compare differences between the interventions in sub-
jective responses and sputum properties data. Paired
t-tests were used to compare respiratory flow between
the interventions. Wilcoxon signed rank tests were
used to determine differences between the interven-
tions in the number of coughs, as these data were
not normally distributed. Statistical significance was
set at p < 0.05.
The difference in sputum mechanical impedance
between interventions was the primary outcome meas-
ure. Data from our previous study showed that 20 par-
ticipants would be required to provide 80% power to
detect the anticipated between group differences as
significant for three of the four measures of sputum
mechanical impedance (alpha 0.05) [15]. We sought to
recruit 25 participants to allow for a 20% dropout and
increase precision around our estimates.
Results
Twenty-five adults with mild to severe CF lung disease
were recruited and 24 completed the study (one partici-
pant withdrew after Visit 1 without giving a reason).
Participant baseline characteristics are presented in
Tables 1 and 2 [29–32]. Routine mucolytic therapy was:
hypertonic saline only for 6 participants; rhDNase only
for 9 participants; both hypertonic saline and rhDNase
for 7 participants. No participant used mannitol and
2 participants did not use any mucolytic medication.
Twenty-one of the 24 participants exercised regularly
when well and 22 performed some form of airway
clearance routinely (3 only exercised; 1 performed
established airway clearance only and 18 performed a
combination of exercise and established airway clear-
ance techniques, including 2 who performed Flutter®
therapy on a regular basis (see Additional file 1 for
full details).
All participants were able to spontaneously expector-
ate a sputum sample at each requested time point. There
were no significant differences in pre-intervention
sputum properties or subjective sense of chest conges-
tion and ease of expectoration on Visits 2, 3 and 4, and
no carry-over or order effect between interventions was
detected (Additional file 1).
Treatment descriptors
Pulse rate, oxygen saturation and treatment descriptors
(work rate and perceived intensity during treadmill
exercise; [33, 34] Flutter® angle, oscillation frequency
and average expiratory pressure) for the 20-min inter-
ventions are presented in Table 3. Treadmill exercise
was moderate intensity for breathlessness and perceived
exertion. All treatments were well-tolerated with no
adverse events.
Table 1 Participant characteristics
Mean ± SD Range
Age (yr) 30 ± 8 19–48
Sex (F : M) 9 : 15
BMI (kg/m2) 21.0 ± 2.2 17.1–26.2
FEV1 (L) 1.81 ± 0.72 0.90–3.40
FEV1 (predicted %) 51 ± 18 28–86
FVC (predicted %) 71 ± 14 46–98
RV/TLC (%) 40 ± 10 24–57
Treadmill peak VO2 (mL/kg/min) 30.6 ± 7.8 18.9–50.5
Treadmill peak VO2 (predicted %) 82 ± 19 48–127
Mean ± standard deviation and range of participant baseline characteristics for
the 24 participants who completed the study. Forced expiratory volume in 1 s
(FEV1), forced vital capacity (FVC) [30] and treadmill peak VO2 [31, 32] expressed
as a percentage of predicted values. Residual volume (RV) divided by total lung
capacity (TLC) reflects the degree of air trapping
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Mucus clearance mechanisms
Respiratory flow
Peak expiratory flow (PEF) was significantly higher dur-
ing treadmill exercise and Flutter® compared to control
(Table 4). Only Flutter® resulted in an expiratory airflow
bias (PEF:PIF > 1.10).
Sputum properties
There were no significant differences in sputum water
content, measured by sputum percent solids, between any
interventions immediately after (post + 0) or after 20-min
recovery (post + 20) (Fig. 3). However, for those who spon-
taneously expectorated a sputum sample in the five
minutes following an intervention (post + 5; n = 12/15/16
for control/exercise/Flutter® therapy respectively), tread-
mill exercise resulted in significantly lower sputum
percent solids than control (pre-post + 5 mean difference
1.2%, 95% CI 0.4 to 1.9) and a trend for lower sputum
percent solids compared to Flutter® therapy (pre-post + 5
mean difference 1.1%, 95% CI −0.1 to 2.3).
Treadmill exercise resulted in significant reductions in
sputum mechanical impedance compared to control both
immediately following the intervention (pre-post + 0 mean
difference at 1 rad/s 7.1 Pa, 95% CI 1.9 to 12.3; at 100 rad/s
32.5 Pa, 95% CI 5.5 to 59.6) and after 20-min recovery (pre-
post + 20 mean difference at 1 rad/s 11.5 Pa, 95% CI 4.0 to
19.1) (Fig. 4). Flutter® therapy resulted in significant reduc-
tions in sputum mechanical impedance both immediately
following the intervention (pre-post + 0 mean difference
6.4 Pa, 95% CI 0.7 to 12.2) and after 20-min recovery (pre-
post + 20 mean difference at 1 rad/s 7.3 Pa, 95% CI 3.3 to
11.2; at 100 rad/s 29.9 Pa, 95% CI 29.9 Pa, 9.0 to 50.9).
There were no significant differences in sputum mechanical
impedance following treadmill exercise compared to Flut-
ter® therapy.
Cough
There were significantly more coughs during treadmill
exercise and Flutter® therapy compared to control, and
during Flutter® therapy compared to treadmill exercise
(Table 5). Note that participants were instructed to
cough 18 times during the FET in the Flutter® therapy
intervention. There were no differences between inter-
ventions in the number of spontaneous coughs during
the 20-min recovery.
Table 2 Baseline sputum properties and subjective reports
Mean ± SD Range
Sputum solids content (%) 6.4 ± 2.6 1.6–13.3
Sputum mechanical impedance
(G*) at 1 rad/s (Pa)
21.0 ± 15.9 5.7–59.1
Sputum mechanical impedance
(G*) at 100 rad/s (Pa)
174.8 ± 76.7 84.1–396.7
Sense of chest congestion (cm) 5.5 ± 2.4 0.5–9.8
Ease of expectoration (cm) 4.9 ± 2.5 0.1–10.0
Mean ± standard deviation and range of sputum properties and subjective reports
for the first sputum sample collected from the 24 participants who completed the
study. Sputum mechanical impedance (G*, the vector sum of sputum viscosity and
elasticity). Subjective sense of chest congestion (0 = very congested, 10 = very clear)
and ease of expectoration (0 = very difficult to expectorate, 10 = very easy to
expectorate) scored by participant on a 10 cm visual analogue scale
Table 3 Treatment descriptors
PR (bpm) SpO2 (%) Treatment descriptors
Control 81 ± 14 96 ± 3 resting breathing
Treadmill 129 ± 18 96 ± 3 5.4 km/h ± 0.7 at 3%
incline ± 3, dyspnoea
3 ± 1, RPE 3 ± 2
Flutter® 84 ± 10 97 ± 2 7.3° ± 3.6 at 17.5 Hz ± 1.7,
31 cmH2O ± 10
Data are presented as mean± standard deviation for group values of the pulse rate
(PR) and oxygen saturation (SpO2), and treatment descriptors (treadmill speed and
incline, modified Borg dyspnoea [34] and modified 0-to-10-point rate of perceived
exertion (RPE) [33]; Flutter® angle and oscillation frequency, average expiratory
pressure). Treadmill work rate was set at the speed and incline equivalent
to 60% of the participant’s peak VO2 achieved on Visit 1 of the study. Flutter® angle
(positive numbers represent an inclination above the horizontal at 0°) was set at the
inclination determined to be the most effective by the senior physiotherapist on
Visit 1 of the study (i.e. that maximised the sensation of vibrations within the lungs)
Table 4 Respiratory flow during the interventions
PEF (L/s) PEF:PIF
Control 0.68 ± 0.28 0.85 ± 0.14
Treadmill 1.68* ± 0.51 0.90 ± 0.10
Flutter® 1.53* ± 0.25 1.13* ± 0.37
Data are presented as mean ± standard deviation for group values of peak
expiratory flow (PEF) and ratio of peak expiratory to peak inspiratory flow
(PEF:PIF). Mean difference and (95% CI): Treadmill v control PEF 1.00 L/s (0.82
to 1.18); Flutter® v control PEF 0.85 L/s (0.69 to 1.01); Flutter® v control PEF:PIF:
0.28 (0.11 to 0.45)
*p < 0.01 compared to control
Fig. 3 Change in sputum hydration. Measured by sputum solids
content, from pre to post intervention (post + 0) and pre to post recovery
(post + 20). A negative change represents an improvement in sputum
hydration. Results are group mean and SE for the control (white),
treadmill exercise (black) and Flutter® therapy (diagonal lines) interventions
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Subjective responses
Treadmill exercise significantly improved subjective ease
of expectoration compared to control after 20-min
recovery (pre-post + 20 mean difference 1.3 cm, 95% CI
0.3 to 2.3) (Fig. 5a). There were no significant differences
in ease of expectoration following Flutter® therapy
compared to control or Flutter® therapy compared to
treadmill exercise.
There were no significant differences in subjective
sense of chest congestion following treadmill exercise
compared to control or treadmill exercise compared to
Flutter® therapy (Fig. 5b). Flutter® therapy significantly
improved subjective sense of chest congestion compared
to control both immediately post intervention (pre-post + 0
mean difference 0.8 cm, 95% CI 0.1 to 1.4) and after
20-min recovery (pre-post + 20 mean difference
0.9 cm, 95% CI 0.2 to 1.7).
Discussion
The primary purpose of this study was to compare
treadmill exercise and Flutter® therapy on mucus clear-
ance mechanisms in CF. The main findings were that
both treadmill exercise and Flutter® resulted in similar
significant increases in PEF, but only Flutter® created an
expiratory airflow bias. In addition both treadmill
exercise and Flutter® therapy resulted in similar signifi-
cant reductions in sputum mechanical impedance, but
only treadmill exercise caused a transient increase in
sputum hydration.
The PEF and airflow bias measured during treadmill
exercise was similar to that reported by our group previ-
ously [15]. The PEF and oscillation frequency measured
during Flutter were higher than previously reported by
our group (1.53 L/s v 1.13 L/s and 17.5 Hz v 11.3 Hz
respectively), yet the airflow bias was similar (1.13 v 1.15),
[17] and above the 1.10 threshold proposed to augment
annular flow of mucus towards the oropharynx [6]. The
higher PEF and oscillation frequency with Flutter® in this
study compared to our earlier work may be explained by
the Flutter® position. In the earlier study the Flutter® was
used in the horizontal position for all participants, [17]
however in the current study the Flutter® inclination was
individually determined (with an average angle 7.3° above
the horizontal). Holding the Flutter® at higher inclinations
results in higher oscillations [35, 36].
The reductions in sputum mechanical impedance
following treadmill exercise were similar to those reported
previously by our group [15]. Different techniques to
measure sputum viscosity and elasticity prevented com-
paring the changes following Flutter® therapy in this study
to those reported by other researchers [18]. Our study
found no significant difference between treadmill exercise
and Flutter® therapy in the reductions in sputum mechan-
ical impedance, suggesting that the combined effects of
shearing forces and airway oscillations with the two inter-
ventions were similar.
There was no change in sputum hydration immedi-
ately following treadmill exercise or after 20 min of
recovery, similar to our previous study [15]. However,
we found a significant reduction in sputum solids con-
tent in the five minutes following treadmill exercise but
Fig. 4 Change in sputum mechanical impedance (G* vector sum of sputum viscosity and elasticity) at (a) 1 rad/s and (b) 100 rad/s. Measured pre
to post intervention (post + 0) and pre to post recovery (post + 20). A negative change represents an improvement in sputum mechanical impedance.
Results are group mean and SE for the control (white), treadmill exercise (black) and Flutter® therapy (diagonal lines) interventions. *p < 0.03





Control 2 (0–5) 1 (0–3)
Treadmill 4* (1–9) 2 (1–5)
Flutter® therapy 24* (18–34) 2 (1–4)
Data are presented as median (interquartile range) for group values of the number
of coughs during the 20-min intervention and 20-min resting breathing/recovery
period. NB. Participants were instructed to cough 18 times during the Flutter®
therapy intervention
*p < 0.01 compared to control
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not after Flutter® therapy. Previously researchers have
shown an inhibition of sodium conductance channels
[11, 12, 37] and altered ion regulation with submaximal
cycle exercise in adults with CF [13], suggesting
improved airway hydration or airway surface liquid,
however these changes only lasted for four minutes after
ceasing exercise [37]. Our study provides some evidence
to support the proposed increase in mucus water con-
tent with exercise in CF [10–12]. The 1.2% reduction in
sputum solids content that we observed is likely to be
clinically significant as it is similar to that achieved with
mannitol in people with CF, [28] which results in signifi-
cant improvements in mucus clearance [38] and lung
function in the long term [39].
Consistent with the improved changes in sputum
properties, participants reported significant improve-
ments in ease of expectoration following treadmill
exercise but not following Flutter® therapy. Alter-
nately, participants reported significant improvements
in subjective sense of chest congestion following Flutter®
therapy but not following treadmill exercise. We did
not measure the amount of sputum expectorated, as
this would have interfered with sputum rheology and
solids content measurements. Perhaps treadmill
exercise facilitated sputum expectoration (due to
increased PEF and reduced sputum mechanical im-
pedance), but participants did not spontaneously
expectorate sufficient sputum to feel less chest con-
gestion. Also, potentially the format of the FET dur-
ing Flutter® treatment (18 directed coughs in 20 min)
increased the amount of sputum expectorated (and
hence sensation of less chest congestion), but it was a
taxing treatment and so participants did not consider
it easier to expectorate.
Conclusions
A single bout of moderate-intensity treadmill exercise
and Flutter® therapy improved mucus clearance mecha-
nisms in adults with CF. Both treatments increased PEF,
but only Flutter® created an expiratory airflow bias. Both
treatments resulted in similar significant reductions in
sputum mechanical impedance, however only treadmill
exercise created a significant transient reduction in
sputum solids content. It would therefore appear that
treadmill exercise and Flutter® therapy are equally effect-
ive in augmenting mucus clearance mechanisms in
adults with CF. Physiological or mechanistic findings on
their own, however, are insufficient to implement
changes to clinical practice. Studies that directly meas-
ure mucus and mucociliary clearance or longer term
studies with clinically important outcomes (such as
exacerbation frequency, antibiotic use, quality of life and
lung function) are required to ascertain the relative
merit of these interventions and to determine if people
with CF can use exercise alone as an adequate form of
airway clearance therapy.
Additional file
Additional file 1. Excel spreadsheet includes participant characteristics,
treatment descriptors, and the results of interventions (respiratory flow
and cough, sputum properties and subjective responses. (XLSX 65 kb)
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